Christopher M. Longshaw, PhD

Senior Director, Scientific Affairs EU
Shionogi B.V., United Kingdom

Disclosure(s): Shionogi: Employee

Poster(s):

• 609 - In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 660 - In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 677 - Systematic Review of the Early Use Experince of Cefiderocol in Real World Practice
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1711 - In Vitro Activity of Cefiderocol Against US Achromobacter spp. and Burkholderia spp. Clinical Isolates from the SENTRY Surveillance Program 2020-2021
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1715 - In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET